LDS/Medical Tests/BRCA1 and BRCA2 Gene Mutations Analysis (duplication/deletion and large gene rearrangements)

BRCA1 and BRCA2 Gene Mutations Analysis (duplication/deletion and large gene rearrangements)

Breast cancer is the most common malignancy among women in the United States and the second most common cause of cancer-related deaths in the U.S. after lung cancer. Each year more than 200,000 women are diagnosed with breast cancer and approximately 40,000 women die every year of breast cancer. Though ovarian cancer ranks 7th in incidence of cancer in women worldwide, it is the most common cause of cancer-related deaths due to gynecological malignancies. In 2014, an estimated 21,980 women will be newly diagnosed with ovarian cancer in the U.S. and 14,270 women will die from it. The lifetime risk of breast cancer is 1 in 8 women (12.3%) while that of ovarian cancer is 1 in 70 (1.4%).

Though most cases of breast and ovarian cancers are sporadic, up to 10% of breast cancers and 15% of ovary cancers are associated with BRCA1 or BRCA2 mutations. BRCA1 is located on chromosome 17 (locus 17q21) and BRCA2 on chromosome 13 (locus 13q12.3). These two genes function as tumor suppressor genes by responding to DNA damage and contributing to its repair. They also are involved in cell cycle regulation and apoptosis. Germline mutations in one copy of BRCA1 or BRCA2 (a heterozygous mutation) tumor suppressor genes strongly predispose to cancers of the breast, ovary, pancreas, and prostate. It is unclear why BRCA1 and BRCA2 mutations affect breast and ovary specifically. Somatic mutations involving BRCA1 and/or BRCA2 in the actual tumors of the breast and ovary are occasionally observed but, by definition, do not have a hereditary component or consequence.

Advancements in molecular genetic techniques, particularly high-throughput sequencing tools, have greatly expanded our understanding of mutations involving BRCA1 and BRCA2. Over 1000 mutations involving both coding and non-coding regions have been described in the literature so far. The most common mutations include small insertions or deletions that lead to frameshift mutations and altered splice-sites resulting in non-functional proteins. Some mutations tend to occur more frequently in specific racial/ethnic groups due to genetic isolation as a result of geographic or cultural separation – a phenomenon often referred to as “founder effect” has been documented in Ashkenazi, Icelandic, French Canadian, Norwegian, African, Latin American/Caribbean and Near/Mideast populations. Though sequencing techniques are robust in identifying BRCA1 and BRCA2 mutations, knowledge of racial/ethnic distribution of these mutations helps determine the technique used to identify a mutation and the specific mutation for which to search since testing cost can be a factor.

  • Diagnostic confirmation of hereditary breast ovarian cancer in affected members
  • To evaluate the risk of developing hereditary breast ovarian cancer in unaffected individuals with significant family history
  • Therapy selection and monitoring in ovarian cancer
  • Positive for mutation – Germline BRCA1/BRCA2 mutation is detected and the patient is at increased risk for breast and ovarian cancers. Genetic testing is recommended for at-risk family members and relatives.
  • Variant of unknown significance – An abnormality in the BRCA1/BRCA2 is detected; however, the risk of breast and ovarian cancers is unknown. Genetic testing for family members and family research studies may be necessary.
  • Negative for mutation – No germline mutations in BRCA1/BRCA2 are identified in the patient; the need for genetic testing for family members depends on family history and clinical suspicion.

Negative for mutations analyzed 

Direct sequencing, Next Generation Sequencing, Denaturing high performance liquid chromatography (DHPLC), Single-strand conformation polymorphism (SSCP), Denaturing gradient gel electrophoresis (DGGE), Heteroduplex analysis (HA), Fluorescent assisted mismatch analysis (FAMA), Protein truncation test (PTT) and Bi-directional targeted sequence analysis.

Whole Blood collected in purple top EDTA tube (preferred) or yellow top citric acetate tube.

Buccal swabs with appropriate buffer and transport media are also acceptable. Extracted genomic DNA is also acceptable provided it meets all the criteria.

Stability

  • Room: 2-3 days
  • Refrigeration: 7 days
  • Frozen: avoid freezing blood.
Diagnostic breast biopsy, Estrogen and progesterone receptor status by immunohistochemistry, Her2/neu by IHC with reflex to FISH if needed, Breast cancer gene expression profile, Ki-67 by IHC, E-cadherin by IHC if necessary.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login